ES2641089T3 - Terapia adyuvante mejorada de tumores que expresan G250 - Google Patents

Terapia adyuvante mejorada de tumores que expresan G250 Download PDF

Info

Publication number
ES2641089T3
ES2641089T3 ES12171081.8T ES12171081T ES2641089T3 ES 2641089 T3 ES2641089 T3 ES 2641089T3 ES 12171081 T ES12171081 T ES 12171081T ES 2641089 T3 ES2641089 T3 ES 2641089T3
Authority
ES
Spain
Prior art keywords
treatment
antigen
antibody
stage
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES12171081.8T
Other languages
English (en)
Spanish (es)
Inventor
Olaf Wilhelm
Sven Warnaar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heidelberg Pharma AG
Original Assignee
Wilex AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex AG filed Critical Wilex AG
Application granted granted Critical
Publication of ES2641089T3 publication Critical patent/ES2641089T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES12171081.8T 2004-07-02 2005-06-29 Terapia adyuvante mejorada de tumores que expresan G250 Expired - Lifetime ES2641089T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58467904P 2004-07-02 2004-07-02
US584679P 2004-07-02

Publications (1)

Publication Number Publication Date
ES2641089T3 true ES2641089T3 (es) 2017-11-07

Family

ID=35431139

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12171081.8T Expired - Lifetime ES2641089T3 (es) 2004-07-02 2005-06-29 Terapia adyuvante mejorada de tumores que expresan G250

Country Status (13)

Country Link
US (1) US7691375B2 (https=)
EP (2) EP1763367A2 (https=)
JP (1) JP2008505143A (https=)
KR (1) KR101205289B1 (https=)
CN (1) CN101052416B (https=)
AU (1) AU2005259481B2 (https=)
BR (1) BRPI0512854A (https=)
CA (1) CA2566950A1 (https=)
DK (1) DK2497497T3 (https=)
ES (1) ES2641089T3 (https=)
MX (1) MXPA06013240A (https=)
RU (2) RU2371198C2 (https=)
WO (1) WO2006002889A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
KR20120082429A (ko) 2009-09-18 2012-07-23 미쓰비시 가가꾸 가부시키가이샤 간세포암 마커
RU2442983C1 (ru) * 2011-01-14 2012-02-20 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
BR112015020061A8 (pt) * 2013-02-22 2018-01-23 Wilex Ag composto alvo anidrase carbônica ix (caix) para tratamento de câncer, seus usos, composição farmcêutica, e método para diagnosticar, prognosticar e/ou classificar um câncer
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) * 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
DK1733736T3 (en) * 2001-02-07 2015-06-01 Wilex Ag A process for the production of recombinant antibodies to tumors
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
RU2257200C1 (ru) * 2004-05-12 2005-07-27 Кутушов Михаил Владимирович Лекарственное средство

Also Published As

Publication number Publication date
CA2566950A1 (en) 2006-01-12
BRPI0512854A (pt) 2008-04-08
RU2371198C2 (ru) 2009-10-27
EP2497497A1 (en) 2012-09-12
JP2008505143A (ja) 2008-02-21
US20070207157A1 (en) 2007-09-06
EP1763367A2 (en) 2007-03-21
RU2519340C2 (ru) 2014-06-10
EP2497497B1 (en) 2017-06-21
MXPA06013240A (es) 2007-02-28
CN101052416A (zh) 2007-10-10
KR20070036085A (ko) 2007-04-02
AU2005259481A1 (en) 2006-01-12
CN101052416B (zh) 2013-07-10
RU2009122344A (ru) 2010-12-20
US7691375B2 (en) 2010-04-06
WO2006002889A2 (en) 2006-01-12
DK2497497T3 (en) 2017-08-14
WO2006002889A3 (en) 2006-10-05
RU2007104040A (ru) 2008-08-10
AU2005259481B2 (en) 2010-04-22
KR101205289B1 (ko) 2012-11-27

Similar Documents

Publication Publication Date Title
RU2519340C2 (ru) Улучшенная вспомогательная терапия опухолей, экспрессирующих g250
ES2938321T3 (es) Métodos para tratar el cáncer de piel mediante la administración de un inhibidor de PD-1
Hitchcock et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin’s lymphoma
ES2703572T3 (es) Tratamiento del cáncer basado en la estratificación de CAIX
WO2019161320A1 (en) Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
Lin et al. Immune microenvironment of primary and recurrent craniopharyngiomas: A study of the differences and clinical significance
Rizzieri et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
Kawashima et al. Dose–volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma
Zavos et al. Study of “de novo” malignancies among Greek renal transplant recipients
Freedman et al. Solitary late recurrence of renal cell carcinoma presenting as duodenal ulcer
Macheiner et al. Sézary syndrome and seronegative polyarthritis: treatment with extracorporeal photochemotherapy
RU2552289C1 (ru) Способ лечения местнораспространенного рака желудка с высокой метаболической и пролиферативной активностью
Dai et al. Camrelizumab (SHR-1210) treatment for recurrent hepatocellular carcinoma after liver transplant: a report of two cases
Kuroda et al. Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report
Marks et al. Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the Ampulla of Vater
Peleaæã et al. Axillary Reverse Mapping Using Indocyanine Green and Concurrent Sentinel Lymph Node Biopsy in Breast Cancer Patients with or without Neoadjuvant Systemic Treatment
Apfelbaum et al. LGG-02. Elucidating the role of fgfr1 alterations in pediatric gliomas
Kuusk Lymphatic drainage in renal tumours and implications for management
Bertagna et al. Massive bilateral adrenal gland metastases from melanoma diagnosed by F18-FDG-PET/CT
Chernyanskaya et al. OPDIVO IN THE TREATMENT OF RECURRENT REFRACTORY HODGKIN'S LYMPHOMA ON THE EXAMPLE OF A CLINICAL CASE
Karyağar et al. The Diagnostic Power of the Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Biochemical Recurrence After Primary Curative Treatment in Patients with Prostate Cancer: A Single-center Experience
KurKomelis Microvasculature of human tumor xenografts: a study of vascular hyperpermeability, fibrinogen influx and fibrin accumulation in two colon carcinomas
Evens et al. 19 Hodgkin lymphoma: epidemiology, diagnosis, and treatment
Iyad Sultan et al. Soft Tissue Sarcomas In Young Individuals
Hadjieva et al. Bulgarian practice in treatment and follow-up of differentiated thyroid cancer.